Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: A modelling study by Phillips, A. (Andrew) et al.
www.thelancet.com/hiv   Published online November 22, 2017   http://dx.doi.org/10.1016/S2352-3018(17)30190-X 1
Cost-effectiveness of public-health policy options in the 
presence of pretreatment NNRTI drug resistance in 
sub-Saharan Africa: a modelling study
Andrew N Phillips, Valentina Cambiano, Fumiyo Nakagawa, Paul Revill, Michael R Jordan, Timothy B Hallett, Meg Doherty, Andrea De Luca, 
Jens D Lundgren, Mutsa Mhangara, Tsitsi Apollo, John Mellors, Brooke Nichols, Urvi Parikh, Deenan Pillay, Tobias Rinke de Wit, Kim Sigaloff, 
Diane Havlir, Daniel R Kuritzkes, Anton Pozniak, David van de Vijver, Marco Vitoria, Mark A Wainberg*, Elliot Raizes, Silvia Bertagnolio, Working 
Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa
Summary
Background There is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) 
resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed 
the effectiveness and cost-effectiveness of alternative public health responses in countries in sub-Saharan Africa 
where the prevalence of pretreatment drug resistance to NNRTIs is high.
Methods The HIV Synthesis Model is an individual-based simulation model of sexual HIV transmission, progression, 
and the effect of ART in adults, which is based on extensive published data sources and considers specific drugs and 
resistance mutations. We used this model to generate multiple setting scenarios mimicking those in sub-Saharan 
Africa and considered the prevalence of pretreatment NNRTI drug resistance in 2017. We then compared effectiveness 
and cost-effectiveness of alternative policy options. We took a 20 year time horizon, used a cost effectiveness threshold 
of US$500 per DALY averted, and discounted DALYs and costs at 3% per year.
Findings A transition to use of a dolutegravir as a first-line regimen in all new ART initiators is the option predicted to 
produce the most health benefits, resulting in a reduction of about 1 death per year per 100 people on ART over the 
next 20 years in a situation in which more than 10% of ART initiators have NNRTI resistance. The negative effect on 
population health of postponing the transition to dolutegravir increases substantially with higher prevalence of HIV 
drug resistance to NNRTI in ART initiators. Because of the reduced risk of resistance acquisition with dolutegravir-
based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this policy option is 
also predicted to lead to a reduction of overall programme cost.
Interpretation A future transition from first-line regimens containing efavirenz to regimens containing dolutegravir 
formulations in adult ART initiators is predicted to be effective and cost-effective in low-income settings in 
sub-Saharan Africa at any prevalence of pre-ART NNRTI resistance. The urgency of the transition will depend largely 
on the country-specific prevalence of NNRTI resistance.
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Introduction
More than 18 million people in sub-Saharan Africa are 
now on antiretroviral therapy (ART). The standard 
WHO-recommended first-line regimen is the non-
nucleoside reverse transcriptase inhibitor (NNRTI) 
efavirenz plus two nucleoside analogue reverse 
transcriptase inhibitors (usually lamivudine [3TC] or 
emtricitabine [FTC]) plus tenofovir disoproxil fumarate 
(TDF).1 Survey results and programme data suggest that 
more than 85% of people receiving treatment in several 
countries in southern Africa have viral loads of less than 
1000 copies per mL.2,3 However, HIV drug resistance, 
particularly to efavirenz, in people initiating ART has 
been increasing, with prevalence of more than 10% 
reported in several countries.4–6 Individuals with NNRTI-
resistant HIV have two to three times greater risk of the 
ART regimen not achieving and maintaining virus 
suppression.7–9 In response to this concern, WHO 
recommends the routine implementation of pretreat-
ment drug resistance surveys in ART initiators to guide 
ART programmatic responses in countries with in-
creased prevalence of pretreatment drug resistance.10–12 
ART initiators include those who have never been 
exposed to antiretroviral drugs and those with previous 
antiretroviral drug exposure, either because they have 
previously initiated ART but since interrupted or 
because they have previously been exposed to 
antiretroviral drugs for prevention of mother-to-child 
transmission of HIV. Pretreatment drug resistance is an 
operational definition and can result from transmitted 
resistance and acquired resistance developed during 
previous use of antiretroviral drugs.
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There are various possible policy options in response to 
increased NNRTI pretreatment drug resistance. One 
option is to test for HIV drug resistance at treatment 
initiation, with use of dolutegravir, the WHO-
recommended alternative first-line regimen instead of 
efavirenz if NNRTI resistance is detected. A second option 
is to transition the standard first-line ART regimen to 
dolutegravir in all ART initiators, obviating the need for 
drug resistance testing in new initiators. Both policies 
could also be considered for implementation only among 
ART initiators with self-reported antiretroviral drug 
exposure, rather than in all ART initiators. Each option has 
different effects on viral suppression, future transmission 
of HIV drug resistance, and, ultimately, clinical disease, 
death, and disability-adjusted life-years (DALYs, a measure 
of overall disease burden that is expressed as the number 
of healthy years of life lost because of illness, disability, or 
early death) incurred in the entire adult population. 
However, responses need to be guided not only by what is 
predicted to be the most effective option for averting 
DALYs in the population but also by cost-effectiveness. If 
the cost per DALY averted is too high, then the resources 
could probably be used elsewhere in the health-care system 
to avert more DALYs.
Here we address the policy problem of how low-income 
countries in sub-Saharan Africa can respond to 
increasing prevalence of NNRTI pretreatment drug 
resistance. The findings of this analysis were considered 
by a WHO Guidelines Development Group tasked to 
develop guidelines for the public health response to 
pretreatment HIV drug resistance.
Methods
Modelling
We use the HIV Synthesis Model, an individual-based 
simulation model of HIV transmission, progression, and 
response to ART that considers specific drugs and 
resistance mutations and has been used to address 
several questions in relation to HIV and ART 
programmes.13–15 In brief, the model generates a popu-
lation of adults who are each tracked throughout their 
lives, at time intervals of 3 months, for HIV testing, 
condomless sex, and risk of HIV acquisition. Those 
people who acquire HIV are tracked in terms of their 
viral load, CD4 cell count, occurrence of WHO 
stage 3 and 4 HIV disease conditions, clinic attendance 
and drop-out, use of specific antiretroviral drugs, 
presence of specific resistance mutations, adherence to 
ART, and toxic effects of ART. Full details are provided in 
the appendix.We assumed that viral load monitoring was 
introduced from 2016, with differentiation of care, using 
the WHO criteria of a confirmed viral load of more than 
1000 copies per mL to define treatment failure.1 
Individuals meeting the treatment failure criteria switch 
to a second-line regimen at a rate consistent with the 
low proportion of people on second-line ART. We ini-
tially based the population’s demographics and features 
of the HIV epidemic and programmatic response around 
those for Malawi, but we ran the model 5000 times, each 
time sampling a value for a range of parameters 
(appendix, p 53) to reflect the diversity across populations 
in sub-Saharan Africa (table). Each of these model runs 
reflects a different potential programmatic situation, 
which we refer to as a setting scenario. Within the model, 
we considered rates of interruption of ART with an 
associated risk of being lost to follow-up and subsequent 
chance of returning to care, a chance that is highest if a 
person becomes sick with a WHO stage 4 condition. For 
the purposes of this work, we considered those returning 
to care (ie, when they return to the same or a new clinic) 
as ART initiators. Additionally, we consider previous use 
of antiretroviral drugs for prevention of mother-to-child 
Research in context
Evidence before this study 
HIV drug resistance, particularly to efavirenz, in people 
initiating antiretroviral therapy (ART) is becoming more 
common, with a prevalence of more than 10% in several 
countries in sub-Saharan Africa. Individuals with HIV resistant 
to non-nucleoside reverse transcriptase inhibitor (NNRTI) 
are at 2–3-fold greater risk of the ART regimen not achieving 
and maintaining virus suppression. The appropriate public 
health response to the increased prevalence of NNRTI drug 
resistance in sub-Saharan Africa is unclear. We searched Web of 
Knowledge for reports in English and published until 
Aug 8, 2017, using the following search terms: hiv* AND 
resistan* AND (efavirenz OR non-nucleoside OR NNRTI) AND 
cost*. Few studies have addressed cost-effectiveness in the 
context of sub-Saharan Africa. We did not identify any 
cost-effectiveness study that included consideration of 
transition to a dolutegravir-containing first-line ART regimen 
as an option for responding to high prevalence of NNRTI 
pretreatment HIV drug resistance.
Added value of this study 
A transition from efavirenz-based first-line regimens to 
regimens based on dolutegravir generic formulations in 
ART initiators is predicted to be effective and cost-effective 
in low-income settings in sub-Saharan Africa. Benefits are 
expected to be particularly substantial in populations with 
high prevalence of HIV drug resistance to NNRTI.
Implications of all the available evidence 
Countries in sub-Saharan Africa with substantial prevalence of 
NNRTI drug resistance in ART initiators should begin to plan a 
managed transition from efavirenz to dolutegravir generic 
formulations in first-line ART regimens. The urgency of the 
transition depends on the country-specific prevalence of 
NNRTI pretreatment HIV drug resistance. 
See Online for appendix
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transmission of HIV and associated risk of NNRTI 
resistance.
For each setting scenario we set 2018 as the baseline 
year with results from a pretreatment drug resistance 
survey available to us. We then projected outcomes and 
costs were the country to implement each of the following 
alternative policy options, which were formulated as part 
of the WHO Guidelines Development Group process: 
(1) no change in policy; (2) for ART initiators with prior 
antiretroviral exposure, introduce resistance test at 
treatment initiation and use of dolutegravir if NNRTI 
resistance is detected; (3) for all ART initiators, introduce 
resistance test at treatment initiation and use dolutegravir 
if NNRTI resistance is detected; (4) for ART initiators 
with previous antiretroviral drug exposure, introduce 
dolutegravir as first-line regimen; and (5) for all ART 
initiators, introduce dolutegravir as first-line regimen. 
We compared predicted outcomes of these policies, 
including the effectiveness (measured as DALYs) and the 
cost-effectiveness in the context of different prevalences 
of NNRTI pretreatment drug resistance.
Properties of dolutegravir were informed by data from 
many studies (eg, Walmsley and colleagues17), and full 
references for statements in the remainder of this section 
are given in the appendix (p 3), which also describes our 
modelling of drug resistance. Illustration of what our 
assumptions lead to in terms of predicted outcomes by 
1 year, 3 years, and 10 years after ART initiation when 
using a dolutegravir-based or an efavirenz-based regimen 
are shown in the appendix (p 9). Specific assumptions 
for dolutegravir were that there is a rate of HIV drug 
resistance acquisition at a similar level to that of the 
boosted protease inhibitor atazanavir/r, which is inferred 
to be 27 times lower than the rate for efavirenz, informed 
by data on the risk of resistance mutations arising. 
Dolutegravir monotherapy leads to resistance, albeit at a 
much lower rate than with efavirenz monotherapy. 
Dolutegravir has also been generally found to be 
associated with lower risk of toxicity than both efavirenz 
and protease inhibitors although it is associated with 
sleep disturbance in some people. We assume that the 
risk of neurological toxicity is half that of efavirenz 
(although we note that the nature of the toxicity is 
different for the two drugs) and that, unlike efavirenz, 
dolutegravir is not associated with risk of rash. This 
reduced risk of toxicity results in a less discontinuation. 
With respect to potency, we made the conservative 
assumption that dolutegravir has 1·5-times the potency 
of efavirenz (lower than boosted protease inhibitors, 
which are assumed to have potency twice that of 
efavirenz). Very small studies suggested dolutegravir 
could be effective as monotherapy but leads to integrase 
inhibitor resistance over time. When used in combination 
with lamivudine, dolutegravir is also effective in inducing 
viral suppression in people who have never experienced 
virological failure of an ART regimen.
Although these formed our base assumptions, we 
considered for our main results the possibility of 
different assumptions for dolutegravir in a small 
proportion of runs (10% of runs with each assumption): 
Median (90% range) 
across setting 
scenarios
Examples of data from settings
HIV prevalence (age 15–49 years) 11% (6–22) Zimbabwe (2015) 14%; Zimbabwe (2016) 14%; Tanzania (2011) 5%; 
Uganda (2011) 9%; Lesotho (2014) 25%
HIV incidence age 15–49 years per 100 person-years 0·72 (0·15–1·95) MPHIA (0·37%); ZAMPHIA (0·66%); ZIMPHIA (0·45%); Justman (2·4%); 
Huerga (0·39%)
Proportion of HIV-positive people diagnosed 79% (60–90) MPHIA (73%); ZAMPHIA (67%); ZIMPHIA (74%); Huerga (75%); Maman (77%)*
Proportion of all HIV-positive people on ART 63% (44–80) ZAMPHIA (57%); MPHIA (64%); ZIMPHIA (64%); Maman (68%); Huerga (52%)
Proportion of ART-experienced people who have 
started second-line (boosted protease inhibitors) ART
4% (0·5–13) Malawi Ministry of Health (1·5%); Haas (sub-Saharan Africa; 3%)
Proportion of people on ART with viral load less than 
1000 copies per mL
83% (71–88) South Africa (60–88% across districts); ZAMPHIA (89%); MPHIA (91%); 
ZIMPHIA (87%); Maman (91%); Huerga (90%)
Percentage of ART-naive ART initiators with NNRTI 
pretreatment drug resistance
Angola (14%); Botswana (8%); South Africa (14%)
In majority virus 10% (1–34)
In minority or majority virus 12% (2–38)
Percentage of ART initiators with previous exposure to 
antiretrovirals
18% (8–35) Proportion of ART initiators is likely to depend on context of discontinuation 
and re-initiation, which is rarely recorded
Percentage of ART initiators with previous exposure 
to antiretrovirals who have NNRTI resistance in 
majority virus
12% (4–26)
MPHIA=Malawi population-based HIV impact assessment. ZAMPHIA=Zambia population-based HIV impact assessment. ZIMPHIA=Zimbabwe population-based HIV impact 
assessment. ART=antiretroviral therapy. NNRTI=non-nucleoside reverse transcriptase inhibitor. A version of this table with references to example data is available in the 
appendix. *See also Kim and colleagues,16 who suggests undisclosed diagnosed HIV.
Table: HIV epidemic and programmatic characteristics of setting scenarios in 2017
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an increased risk of viral load rebound beyond that for 
efavirenz (not necessarily with HIV drug resistance 
because of, for example, reduced drug concentration 
when used together with rifampicin); that potency of 
dolutegravir could be the same potency or two times the 
potency of efavirenz; and that the risk of neurological 
toxic effects of dolutegravir could be equal to that of 
efavirenz. These small probabilities were selected on the 
basis that we considered such assumptions unlikely to 
hold.
In a further sensitivity analysis, we also considered a 
worst plausible case scenario for dolutegravir. In this 
case, we assumed a higher risk of viral load rebound than 
in our base case (ie, we assumed this for 100% of runs 
rather than for 10% of runs as in our main results). Some 
reports suggest that risk of immune reconstitution 
inflammatory syndrome (IRIS) in people with low 
CD4 cell count at start of ART is greater with dolutegravir 
than with efavirenz. We thus assumed in our worst 
plausible case for dolutegravir a 20% risk of IRIS in the 
first 3 months of dolutegravir-based ART in individuals 
with a CD4 cell count of less than 100 cells per µL, 
compared with 5% risk of IRIS for efavirenz. We also 
assumed that IRIS incurs a $100 hospitalisation cost and 
is associated with a 5% mortality risk. Although no safety 
concerns were raised, there is a lack of safety data for 
dolutegravir in pregnancy. We assumed a 1% risk of 
drug-related birth defect (compared with no assumed 
risk for efavirenz), which is assumed to lead to a 
0·2 disability weight incurred for 5 years for the mother. 
Finally, since transition of the first-line regimen could 
lead to disruption and drug stock-outs, we assumed an 
increase of five times in the stock-outs in the first year of 
dolutegravir introduction.
Cost-effectiveness analysis
Programme costs resulting from the policy options were 
considered as part of a full economic evaluation. The 
purpose of a cost-effectiveness analysis is to inform how 
population health can be improved from within available 
health-care resources. A health-sector perspective has 
therefore been adopted, so direct and indirect costs 
incurred by the patients are not included. We consider 
a 20 year time perspective from 2018 to 2038. Both costs 
and health benefits were discounted to present value 
with a 3% per annum discount rate in our base case. 
Absolute costs and DALYs are relevant for a country with 
a population size of about 10 million adults in 2016 
(similar to Malawi).
For some analyses, we used net DALYs to compare 
policy options. This compares the health benefits from a 
policy with the associated health opportunity costs, 
resulting from the use of limited resources consequentially 
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Figure 1: Predicted mean outcomes for 2018–38 according to policy option 
for setting scenarios where more than 10% of initiators have NNRTI 
resistance in 2017 (mean over all 3 month periods in 20 years; n=2915)
Data are mean differences in percentage relative to no change in policy (95% CI; 
90% range). Option 1: no change. Option 2: drug resistance tests for ART initiators 
with previous antiretroviral exposure. Option 3: drug resistance tests for all ART 
initiators. Option 4: first-line dolutegravir for people with previous ART exposure. 
Option 5: first-line dolutegravir for all ART initiators. (A) Mean percent with viral 
load <1000 copies per mL 1 year from ART initiation. (B) Mean percent of ART 
initiators with NNRTI resistance (NNRTI pretreatment drug resistance). (C) Mean 
percent of people with viral load less than 1000 copies per mL at any time after 
start of ART. (D) Mean mortality in people on ART. (E) Mean incidence of HIV 
infection. ART=antiretroviral therapy. NNRTI=non-nucleoside reverse transcriptase 
inhibitor.
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being unavailable for other interventions in the public 
health-care system.18 Health opportunity costs are captured 
by converting the costs to the health-care system into 
health losses using the cost-effectiveness threshold, which 
reflects the cost per DALY averted of forgone interventions 
that can no longer be provided. Net DALYs are calculated 
as the sum of DALYs plus the ratio of costs to the cost-
effectiveness threshold (ie, the health opportunity costs). 
The cost-effectiveness threshold for a country is not 
readily apparent, but in most sub-Saharan African 
settings, $500 per DALY averted is probably at the upper 
end of the threshold in view of the magnitude of benefit 
for alternative HIV interventions, but the threshold is 
likely to be even lower for other health-care activities.19,20 
The difference in net DALYs between adoption of a 
strategy and no policy change (incremental net DALYs) 
shows the net effect of the strategy on population burden 
of disease. The strategy with the lowest net DALYs 
incurred overall is deemed cost-effective.
Disability weights to calculate DALYs were derived from 
a comprehensive dataset (appendix p 63).21 Costs of 
generic antiretroviral formulations used are as follows: 
$100 per year for efavirenz plus lamivudine plus tenofovir 
disoproxil fumarate ($38 per year for efavirenz alone); 
$106 per year for dolutegravir plus lamivudine plus 
tenofovir disoproxil fumarate ($44 for dolutegravir); and 
$286 per year for atazanavir/r plus lamivudine plus 
zidovudine ($213 for atazanavir/r).22,23 HIV drug resistance 
genotyping tests cost $100, as specified by the WHO 
HIVResNet group. We assume a country transition of 
first-line regimen of $100 000, which is conceived as the 
one-off cost incurred in the country for organising and 
making the transition of regimen, including the training 
of clinic and pharmacy staff. This cost is uncertain, but 
programmes have previously transitioned regimens, 
including from nevirapine to efavirenz and from stavudine 
to tenofovir disoproxil fumarate. Other unit costs are 
detailed in the appendix. Modelling and cost-effectiveness 
analysis was implemented with SAS version 9.4.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The range of HIV epidemic and programmatic 
characteristics of setting scenarios in 2017 generally 
reflected those observed in the region (table). We 
predicted outcomes for the next 20 years according to 
policy for setting scenarios in which more than 
10% (median 19%) of all ART initiators have NNRTI 
pretreatment drug resistance in 2017 (figure 1). We 
calculated the mean percentage of ART initiators with 
viral load less than 1000 copies per mL 1 year from ART 
initiation over the 20 years and found a substantial 
predicted positive effect of using dolutegravir in all ART 
initiators and some positive effect of HIV drug resistance 
testing, with choice of dolutegravir in those with detected 
NNRTI pretreatment drug resistance (figure 1A). We also 
calculated the mean percentage of ART initiators with 
NNRTI pretreatment drug resistance and found that 
with no change in policy, the prevalence of NNRTI 
pretreatment drug resistance is predicted to be more 
than 30% on average over 2018–38, and only the policy of 
using dolutegravir in all ART initiators is predicted to 
substantially reduce NNRTI pretreatment drug resistance 
(figure 1B). We also found a predicted beneficial effect of 
dolutegravir for all ART initiators on the mean percentage 
of all people on ART with viral load of less than 
1000 copies per mL and some benefit of pretreatment 
HIV drug resistance testing, with choice of dolutegravir 
in individuals with NNRTI resistance (figure 1C). 
Mortality in people on ART is predicted to follow a 
similar pattern, with use of dolutegravir in ART initiators 
leading to a reduction of 1 death per year per 100 people 
on ART and the use of pretreatment HIV drug resistance 
testing reducing mortality by 0·6 deaths per year per 
100 people on ART (figure 1D). There is also a predicted 
reduction in HIV infection incidence of about 10% with 
adoption of the policy of using dolutegravir in all ART 
initiators (figure 1E).
We analysed the costs of each policy in the context of 
setting scenarios where more than 10% of ART initiators 
have NNRTI pretreatment drug resistance in 2017 
(figure 2). Despite the slightly higher cost of dolutegravir 
assumed compared with efavirenz, the policy of using 
dolutegravir in ART initiators is the lowest-cost policy, 
primarily because less of the costly second-line boosted 
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Figure 2: Mean annual cost for 2018–38 according to policy option for 
setting scenarios where more than 10% of ART initiators have NNRTI 
resistance in 2017
Option 1: no change. Option 2: drug resistance tests for ART initiators with 
previous antiretroviral exposure. Option 3: drug resistance tests for all ART 
initiators. Option 4: first-line dolutegravir for people with previous ART 
exposure. Option 5: first-line dolutegravir for all ART initiators. 95% CIs are 
generally narrow (appendix, p 13). ART=antiretroviral therapy. 
NNRTI=non-nucleoside reverse transcriptase inhibitor.
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protease inhibitor regimen is used. The policy of HIV 
drug resistance testing with choice of dolutegravir in 
those with detected NNRTI pretreatment drug resistance 
also leads to no increase in costs compared with no 
change in policy, for the same reason. The policy of using 
dolutegravir in all ART initiators is predicted to avert the 
most DALYs and has the lowest cost. The association of 
this policy with the lowest incremental net DALYs 
suggests it is the policy of choice (figure 3).
So far, all results have focused on setting scenarios in 
which more than 10% of ART initiators have NNRTI 
pretreatment drug resistance in 2017. We also considered 
the cost-effectiveness of the policy alternatives according to 
the prevalence of NNRTI pretreatment drug resistance 
(appendix, p 10). The difference in net DALYs compared 
with no change in policy indicates that the policy of using 
dolutegravir in ART initiators is the most cost-effective at 
any prevalence of NNRTI pretreatment drug resistance. 
The higher the prevalence of NNRTI pretreatment drug 
resistance, the greater the extent of the benefit in cost-
effectiveness by moving to a policy of using dolutegravir in 
ART initiators.
So far we have considered the overall proportion of all 
ART initiators with NNRTI pretreatment drug resistance. 
We also assessed the most cost-effective policy according 
to both the percentage of ART initiators with prior 
antiretroviral resistance with NNRTI pretreatment drug 
resistance and the percentage of ART initiators without 
prior antiretroviral drug exposure with NNRTI 
pretreatment drug resistance, each in 2017 (appendix, 
p 11). In each case, the policy of using dolutegravir in ART 
initiators is the most cost-effective.
We then considered the absolute difference in mortality 
(number of deaths per 1000 people on ART per year) and 
the percentage difference in cost for the policy of using 
dolutegravir instead of efavirenz in all ART initiators, 
according to the proportion of all ART initiators with 
NNRTI pretreatment drug resistance in 2017 (figure 4). 
We found a mortality benefit of the policy of using 
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dolutegravir in all ART initiators even in the category 
with lowest NNRTI pretreatment drug resistance, 
reflecting the benefit of dolutegravir observed in 
randomised trials (appendix p 4) of people without prior 
ART resistance. However, the extent of benefit from 
transition to such a policy improves substantially with 
increasing NNRTI pretreatment drug resistance. For 
setting scenarios with a prevalence of NNRTI 
pretreatment drug resistance of 10–12·5% in 2017, no 
change and failure to adopt a policy of using dolutegravir 
in all ART initiators translates into a median of 
5500 additional deaths per year (90% range 1050–16 750) 
on average in the next 20 years. For setting scenarios with 
a prevalence of NNRTI pretreatment drug resis-
tance of 17·5–20%, 9000 additional deaths per year 
(2600–20 650) are expected in the next 20 years if there is 
no change in policy and a policy of using dolutegravir in 
all ART initiators is not adopted.
In the sensitivity analysis, we found that a worst plausible 
case scenario for the properties of generic dolutegravir 
(while maintaining an annual cost of dolutegravir of $44) 
has little effect on our overall conclusions, with the change 
in policy to use dolutegravir in all ART initiators predicted 
to be the most effective policy and to be cost-saving 
(appendix, p 11).
Discussion
The results of our modelling-based analysis predict that 
transition to use of dolutegravir instead of efavirenz in 
regimens for all ART initiators is likely to bring health 
benefits irrespective of the level of NNRTI pretreatment 
drug resistance because of its higher potency, lower risk of 
selection for resistance, and lower incidence of 
discontinuation because of toxicity. However, the extent of 
benefits is predicted to be greatest in settings with high 
levels of NNRTI pretreatment drug resistance. 
Programmes in settings with even moderately increased 
NNRTI pretreatment drug resistance should plan to 
transition to use dolutegravir as a first-line drug; as well as 
being cost-effective, this is likely to also  be cost saving. The 
appropriate timescale for such plans will depend on several 
factors, of which the actual current level of NNRTI 
pretreatment drug resistance is an important one. A 
generic, fixed-dose combination of dolutegravir plus 
lamivudine plus tenofovir disoproxil fumarate is expected 
to be available in 2018. A recent announcement24 suggests 
that the cost of this regimen has become lower than that 
assumed in our modelling ($75 per year compared with 
$106), suggesting an even greater cost saving than that we 
projected. As a result of the WHO Guidelines Development 
Group process, at which these results were presented, a 
consensus statement was made that countries in which 
the prevalence of pretreatment HIV drug resistance to 
NNRTIs among people initiating first-line ART, 
irrespective of previous ARV drug exposure, is 10% or 
more should urgently consider an alternative first-line 
ART regimen that does not contain NNRTIs.9 The WHO 
alternative first-line drug to an NNRTI in the 2016 
guidelines is dolutegravir.
Although recommended as part of first-line therapy in 
high income settings,25 some uncertainties remain over 
dolutegravir use. Data on safety in pregnancy are only 
just accumulating.26 There is also a concern that an 
interaction between dolutegravir and the tuberculosis 
drug rifampicin could reduce drug levels when used 
concomitantly, leading to excess risk of virological failure 
if the dose of dolutegravir is not increased.27 It remains 
unclear whether the extent of the reduction is such that 
that increasing the dolutegravir dose (from once to twice 
a day) is required when coadministered with rifampicin, 
given that dolutegravir is known to be efficacious at a 
dose one fifth of the standard dose (appendix, p 6). Lastly, 
some reports suggest that dolutegravir initiated in people 
with low CD4 cell count is associated with an increased 
risk of IRIS, which would result in increased health-care 
costs and a small excess mortality risk (appendix, p 8). We 
factored these risks into our worst plausible case for 
dolutegravir, but they did not change our conclusion. 
Venter and colleagues28 discussed prospects for 
transitioning to new regimens in sub-Saharan Africa, 
and transition has already started in Botswana and Brazil.
Although we considered a policy of using dolutegravir 
in all new ART initiators, we could also have considered 
a wider introduction of the drug for all people on first-line 
efavirenz-based ART. This policy is predicted to bring 
further health benefits,29 and ART programmes might 
find it easier to make a wholesale transition in all people 
on first-line ART, but we do not present results on this 
potential policy here. Likewise, here we have not 
considered the possibility of use of dolutegravir in 
second-line regimens, as considered elsewhere.30 We 
have focused on changes in policy to deal with the fact 
that, due to existence of NNRTI pretreatment drug 
resistance, the first-line ART regimen will not be fully 
effective in some people. However, the identification of 
high levels of pretreatment drug resistance should also 
prompt consideration of other programmatic improve-
ments, such as strengthening of adherence, supporting 
retention, and increasing switching to second-line regi-
mens in people with virological failure.
We are not aware of other studies of cost-effectiveness 
of transition to dolutegravir in sub-Saharan Africa. In a 
recent study of the cost-effectiveness of pretreatment 
drug resistance testing in Kenya,31 a low-cost point 
mutation assay ($30) before ART initiation was predicted 
to be very cost-effective. Such assays (adapted for 
integrase mutations) might eventually have a role in 
testing for resistance in people with increased viral load 
on first-line dolutegravir to identify if there is a need to 
switch regimen.
Modelling studies of projected mortality differences 
between available policy options become necessary when 
data on direct benefits of dolutegravir are only available 
for potential intermediate outcomes of viral load, 
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resistance, and toxicity. The fact that differences in the 
ability of drug regimens to result in viral suppression 
does ultimately translate into differences in risk of AIDS 
and death is the basis of the reason why the FDA in 
1997 moved from approving antiretroviral drugs on the 
basis of clinical endpoint data to approving them on the 
basis of viral load endpoint data.32
In our model, we capture the fact that some people 
discontinue ART and become disengaged from care and 
that this is more likely in people who are poorly adherent 
or for whom ART is failing, or both. These people are 
therefore likely to have NNRTI drug resistance.33–35 
Nevertheless, model outputs for the proportion of ART 
initiators with NNRTI pretreatment drug resistance who 
have previous antiretroviral drug exposure were not 
substantially higher than for those who have no previous 
antiretroviral drug exposure, which is in contrast with 
survey findings of pretreatment drug resistance that 
show markedly higher levels. This implies an even 
greater tendency for interruption of ART to be more 
likely in those with poor adherence than was assumed, 
which might imply that the policies just targeted at those 
with previous antiretroviral drug exposure could be more 
effective than we have shown.
Our work has several limitations. As is inevitable for a 
cost-effectiveness analysis with an appropriately long-
time horizon, which is required to consider the future 
consequences of current decisions, we rely on a model to 
give predictions of the long-term effect of the alternative 
policies. Our model is particularly detailed and relies on 
many assumptions, although these have generally been 
well informed by a wide array of observed data, albeit not 
always directly from the region itself. The benefits of 
dolutegravir compared with efavirenz are also well 
supported by data. We note that, since our model includes 
adults only, the potential beneficial effects of dolutegravir 
for people younger than 15 years have not been included, 
and we did not consider effects on transmission to 
children. Furthermore, our focus is on low-income 
settings in sub-Saharan Africa. Generic dolutegravir is 
unavailable elsewhere, and cost-effectiveness of the 
transition is likely to be country-specific and dependent 
on the cost of dolutegravir and to be affected by costs of 
other drugs and availability of HIV drug resistance testing 
capacity. Although drug prices can decrease over time, 
there is generally a floor price determined by the 
production cost, so generic drug prices might well not 
now decrease markedly over time in the future.
In conclusion, a transition from efavirenz-containing 
first-line regimens to generic dolutegravir-containing 
regimens is predicted to be effective and cost-effective 
in low-income settings in sub-Saharan Africa at any level 
of NNRTI pretreatment drug resistance. However, with 
high prevalence of NNRTI pretreatment drug resistance, 
the negative effect on the population health of post poning 
the transition to dolutegravir increases sub stantially and 
thus increases the urgency of this intervention.
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